Search

Tutorial on acute leukemia held in Istanbul

EHA and the Turkish Society of Hematology (TSH) partnered for the seventh time to organize a tutorial.

Read more

The EHA Guidelines Workshop, a meaningful and successful first Series!

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

EHA-AHA Hematology Tutorial on Lymphoid Malignancies

Dates: October 18-20, 2019
Location: Yerevan, Armenia
Chairs: G Gaidano, S Danielyan, Y Hakobyan

2019 marks the 3rd time EHA is organizing a tutorial in collaboration with the Armenian Hematology Association (AHA), this time on “Lymphoid Malignancies”.

Read more

Meeting program

Thursday, April 18*All times are in EET. 16:00 - 19:00 EET Satellite symposia

Novartis
Hoffman-La Roche
Takeda
Various satellite symposia will take place the day before the meeting for national and regional participants.

Read more

EHA-PTHiT Hematology Mini Tutorial

Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)

As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more